Menu Back toSession-1-PDUFA-VI-Pilot-Programs-Overview-and-Expectation

Biostatistics Industry and Regulator Forum

Session 1: PDUFA VI Pilot Programs: Overview and Expectation

    Session Chair(s)
      Dionne  Price, PhD

      Dionne Price, PhD

      • Director, Division of Biometrics IV, Office of Biostatistics, OTS, CDER
      • FDA, United States
      Cristiana  Mayer, PhD

      Cristiana Mayer, PhD

      • Scientific Director, Statistical Modeling and Methodology, SDS
      • Janssen Research and Development LLC, United States
    As the landscape of drug development evolves, we are faced with new and different challenges. Consequently, the PDUFA VI goals letter outlines several commitments designed to identify and develop strategies to address these challenges. The commitments include the launch of two distinct pilot programs. The Complex Innovative Designs (CID) pilot seeks to facilitate the advancement and use of complex adaptive, Bayesian, and other novel clinical trial designs. The Model Informed Drug Development (MIDD) pilot will aid in the development and application of exposure-based, biological, and other models derived from preclinical and clinical data sources. Speakers in this session will provide a brief overview and highlight key aspects of the CID pilot as well as the MIDD pilot. A panel discussion will follow to expand on expectations from industry and regulators.

Contact us

Registration Questions?

Send Email

Call for Abstracts

Guidelines | Submit

Submission Deadline: February 12